These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20386106)

  • 1. The effect of HAART on HIV RNA trajectory among treatment-naïve men and women: a segmental Bernoulli/lognormal random effects model with left censoring.
    Chu H; Gange SJ; Li X; Hoover DR; Liu C; Chmiel JS; Jacobson LP
    Epidemiology; 2010 Jul; 21 Suppl 4(0 4):S25-34. PubMed ID: 20386106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model.
    Cole SR; Hernán MA; Anastos K; Jamieson BD; Robins JM
    Am J Epidemiol; 2007 Jul; 166(2):219-27. PubMed ID: 17478436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring.
    Li X; Chu H; Gallant JE; Hoover DR; Mack WJ; Chmiel JS; Muñoz A
    J Epidemiol Community Health; 2006 Sep; 60(9):811-8. PubMed ID: 16905728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model.
    Chu H; Gange SJ; Yamashita TE; Hoover DR; Chmiel JS; Margolick JB; Jacobson LP
    Am J Epidemiol; 2005 Oct; 162(8):787-97. PubMed ID: 16135508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent genital tract HIV-1 RNA shedding after change in treatment regimens in antiretroviral-experienced women with detectable plasma viral load.
    Venkatesh KK; DeLong AK; Kantor R; Chapman S; Ingersoll J; Kurpewski J; De Pasquale MP; D'Aquila R; Caliendo AM; Cu-Uvin S
    J Womens Health (Larchmt); 2013 Apr; 22(4):330-8. PubMed ID: 23531097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.
    Cu-Uvin S; Caliendo AM; Reinert S; Chang A; Juliano-Remollino C; Flanigan TP; Mayer KH; Carpenter CC
    AIDS; 2000 Mar; 14(4):415-21. PubMed ID: 10770544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.
    ; Patel D; Cortina-Borja M; Thorne C; Newell ML
    Clin Infect Dis; 2007 Jun; 44(12):1647-56. PubMed ID: 17516411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS.
    North TW; Higgins J; Deere JD; Hayes TL; Villalobos A; Adamson L; Shacklett BL; Schinazi RF; Luciw PA
    J Virol; 2010 Mar; 84(6):2913-22. PubMed ID: 20032180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study.
    Berhane K; Karim R; Cohen MH; Masri-Lavine L; Young M; Anastos K; Augenbraun M; Watts DH; Levine AM
    J Acquir Immune Defic Syndr; 2004 Oct; 37(2):1245-52. PubMed ID: 15385731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
    Geretti AM; Harrison L; Green H; Sabin C; Hill T; Fearnhill E; Pillay D; Dunn D;
    Clin Infect Dis; 2009 May; 48(9):1296-305. PubMed ID: 19331585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with 10 years of continuous viral load suppression on HAART.
    Bello KJ; Mesner O; O'Bryan TA; Won SH; Lalani T; Ganesan A; Agan BK; Okulicz JF
    BMC Infect Dis; 2016 Jul; 16():351. PubMed ID: 27449671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load.
    Lepri AC; Miller V; Phillips AN; Rabenau H; Sabin CA; Staszewski S
    AIDS; 2001 Jan; 15(1):47-54. PubMed ID: 11192867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.